- Home
- BBAI vs BEAM Comparison
BBAI vs BEAM Comparison
Compare BBAI & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBAI
- BEAM
- Stock Information
- Founded
- BBAI 2020
- BEAM 2017
- Country
- BBAI United States
- BEAM United States
- Employees
- BBAI N/A
- BEAM N/A
- Industry
- BBAI EDP Services
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BBAI Technology
- BEAM Health Care
- Exchange
- BBAI Nasdaq
- BEAM Nasdaq
- Market Cap
- BBAI 1.7B
- BEAM 1.6B
- IPO Year
- BBAI N/A
- BEAM 2020
- Fundamental
- Price
- BBAI $7.71
- BEAM $20.01
- Analyst Decision
- BBAI Strong Buy
- BEAM Strong Buy
- Analyst Count
- BBAI 3
- BEAM 11
- Target Price
- BBAI $6.17
- BEAM $48.90
- AVG Volume (30 Days)
- BBAI 191.6M
- BEAM 2.0M
- Earning Date
- BBAI 07-31-2025
- BEAM 08-05-2025
- Dividend Yield
- BBAI N/A
- BEAM N/A
- EPS Growth
- BBAI N/A
- BEAM N/A
- EPS
- BBAI N/A
- BEAM N/A
- Revenue
- BBAI $159,872,000.00
- BEAM $63,578,000.00
- Revenue This Year
- BBAI $8.26
- BEAM N/A
- Revenue Next Year
- BBAI $12.09
- BEAM $8.82
- P/E Ratio
- BBAI N/A
- BEAM N/A
- Revenue Growth
- BBAI 9.40
- BEAM N/A
- 52 Week Low
- BBAI $1.17
- BEAM $13.53
- 52 Week High
- BBAI $10.36
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- BBAI 79.87
- BEAM 68.31
- Support Level
- BBAI $3.78
- BEAM $16.59
- Resistance Level
- BBAI $7.23
- BEAM $17.38
- Average True Range (ATR)
- BBAI 0.70
- BEAM 1.10
- MACD
- BBAI 0.35
- BEAM 0.35
- Stochastic Oscillator
- BBAI 88.55
- BEAM 89.70
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment. Company generate revenue by providing customers with Edge AI-powered decision intelligence solutions and services for data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics and predictive visualization. It generate revenue from providing both software and services to customers.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.